A pilot safety and feasibility study of concurrent capecitabine (Xeloda) and external beam irradiation in the adjuvant treatment of high risk early stage breast cancer.

Trial Profile

A pilot safety and feasibility study of concurrent capecitabine (Xeloda) and external beam irradiation in the adjuvant treatment of high risk early stage breast cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2009

At a glance

  • Drugs Capecitabine (Primary)
  • Indications Early breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 27 Dec 2008 Planned end date (1 Sep 2009) added as reported by ClinicalTrials.gov.
    • 13 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top